stoxline Quote Chart Rank Option Currency Glossary
Galapagos NV (GLPG)
25.74  0.3 (1.18%)    06-17 16:00
Open: 25.88
High: 25.88
Volume: 122,820
Pre. Close: 25.44
Low: 25.32
Market Cap: 1,696(M)
Technical analysis
2024-06-17 5:23:44 PM
Short term     
Mid term     
Targets 6-month :  33.38 1-year :  35.74
Resists First :  28.58 Second :  30.6
Pivot price 26.74
Supports First :  25.31 Second :  21.06
MAs MA(5) :  25.82 MA(20) :  27.09
MA(100) :  32.14 MA(250) :  35.79
MACD MACD :  -0.9 Signal :  -0.8
%K %D K(14,3) :  7.7 D(3) :  4.5
RSI RSI(14): 27.8
52-week High :  44.25 Low :  25.31
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ GLPG ] has closed above bottom band by 16.4%. Bollinger Bands are 11.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 25.94 - 26.11 26.11 - 26.27
Low: 24.89 - 25.11 25.11 - 25.31
Close: 25.4 - 25.75 25.75 - 26.06
Company Description

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Headline News

Mon, 17 Jun 2024
Galapagos Unveils Promising Cancer Therapy Data - TipRanks

Thu, 13 Jun 2024
Galapagos (NASDAQ:GLPG) Hits New 12-Month Low at $25.95 - MarketBeat

Fri, 07 Jun 2024
Galapagos (NASDAQ:GLPG) Sets New 12-Month Low at $26.85 - MarketBeat

Mon, 06 May 2024
Galapagos NV (NASDAQ:GLPG) Q1 2024 Earnings Call Transcript - Yahoo Finance

Fri, 19 Apr 2024
Galapagos NV (AMS:GLPG) Analysts Are More Bearish Than They Used To Be - Simply Wall St

Wed, 17 Apr 2024
Citi lowers Galapagos NV shares target amid restructuring and pipeline investments By -

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 66 (M)
Shares Float 45 (M)
Held by Insiders 0 (%)
Held by Institutions 31.7 (%)
Shares Short 1,570 (K)
Shares Short P.Month 1,500 (K)
Stock Financials
EPS 0.5
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 43.93
Profit Margin 114.4 %
Operating Margin -53.1 %
Return on Assets (ttm) -1.4 %
Return on Equity (ttm) 1.1 %
Qtrly Rev. Growth 6.5 %
Gross Profit (p.s.) 0
Sales Per Share 3.69
EBITDA (p.s.) -1.14
Qtrly Earnings Growth 291.3 %
Operating Cash Flow -434 (M)
Levered Free Cash Flow -214 (M)
Stock Valuations
PE Ratio 50.47
PEG Ratio -1.7
Price to Book value 0.58
Price to Sales 6.96
Price to Cash Flow -3.92
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android